Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axogen, Inc. - Common Stock (NQ:AXGN)

18.36 -0.63 (-3.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axogen, Inc. - Common Stock

< Previous 1 2 Next >
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. To Host Analyst & Investor Day on March 4th
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Craig Swandal, experienced medical device manufacturing executive, joins leadership team 
From Axogen, Inc.
Via GlobeNewswire
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
From Axogen, Inc.
Via GlobeNewswire
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents CFO Kathleen P. Bloch Retires 
From CytoSorbents
Via GlobeNewswire
Axogen, Inc. Announces New Leadership Appointments
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Reports Second Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
From Axogen, Inc.
Via GlobeNewswire
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Showcasing Axogen’s Dedication to Fueling Ohio’s Biotechnology Sector Growth 
From Axogen, Inc.
Via GlobeNewswire
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc Reports First Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
From Axogen, Inc.
Via GlobeNewswire
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
From Axogen, Inc.
Via GlobeNewswire
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Promotions on Research and Development Team
Company Also Announces Departure of Angelo Scopelianos, Ph.D. 
From Axogen, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.